GB2378383A - Nasal delivery of pharmaceutical compositions in powder form - Google Patents
Nasal delivery of pharmaceutical compositions in powder form Download PDFInfo
- Publication number
- GB2378383A GB2378383A GB0113725A GB0113725A GB2378383A GB 2378383 A GB2378383 A GB 2378383A GB 0113725 A GB0113725 A GB 0113725A GB 0113725 A GB0113725 A GB 0113725A GB 2378383 A GB2378383 A GB 2378383A
- Authority
- GB
- United Kingdom
- Prior art keywords
- delivery
- nasal
- pharmaceutical compositions
- powder form
- powder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention relates to methods of preparation of vaccines and pharmaceutical compositions for Nasal delivery. The nasal method of delivery of medicaments comprises new ways of treatment of individuals. The objective of the invention is to develop needle free drug delivery systems to facilitate faster delivery to the target in lower dosage. The introduction of the medicament in powder form in the nose by relative ease is attractive method in terms of patient compliance the other aspect of the invention relates to the Nasal delivery of pharmaceutical compositions of neurologic agents by means of olfactory neutral pathways. Theses agents included naturally occurring nerve growth promoting factors including phosphotidyl serine, insulin and insulin like growth factors.
Description
<Desc/Clms Page number 1>
Nasal Delivery of pharmaceutical compositions including vaccines and
biotechnological products.
Patent Application Number: By Dr Gursharan Moonga of BntHealth Drug Technologies, Business & Technology Centre, Bessemer Drive, Stevenage, Herts. SG 1 2DX England Description: The invention relates to methods of preparation of pharmaceutical and vaccines compositions for Nasal delivery. The nasal method of delivery of medicaments comprises new ways of treatment of individuals. The objective of the invention is to develop needle free drug delivery systems to facilitate faster delivery to the target in lower dosage.
The introduction of the medicament in powder form in the nose by relative ease is attractive method in terms of patient compliance the other aspect of the invention relates to the Nasal delivery of pharmaceutical compositions of neurologic agents by means of olfactory neutral pathways. Theses agents included naturally occurring nerve growth promoting factors including phosphotidyl serine, insulin and insulin like growth factors.
Background to the Invention: There are three main reasons for delivery of medicaments via the nose; a) Convenience b) Topical effect on the epithelium lining c) Systemic effect-superficial vessels can facilitate rapid absorption directly into the blood stream.
The nasal cavity area for drug absorption measuring approx 160cm2 and the turbulent airflow through the nose encourages inertial impaction of suspended particles into blanket of mucous covering highly vascularised nasal mucousa. The rapid passage of drugs across the nasal epithelium and into blood stream is the major advantage of nasal route of delivery, making the nose an ideal alternative to inject able route for some acute treatments as well as maintenance therapies currently delivered by injection. The delivery of medicaments and vaccines or peptides by Nasal route is promising as these areas have less enzymatic activity which might destroy polypeptides The problems have been encountered I the past for nasal delivery of macromolecules as only small portion of the drug could be absorbed. The other barrier of nasal bioavailability included mucocilliary clearance of the drug to the back of throat. The administration of peptides with aqueous nasal sprays has also proved problematic to include low bioavailability, local irritation of nasal mucosa.
The invention relates to the medicaments in a carrier system in powder form (in preservative free form to avoid irritation) manufactured using spray method of the active medicament on a carrier dextrin powder or locust bean powder, or Soya powder or milk powder which is inhaled by a device and active medicament comes in direct contact with mucosa and contributes to higher absorption These biotechnological products are more stable in dry solid state. It has been demonstrated by Scientists that a powder formulation remains longer on the nasal mucosa than a liquid formulation and particle size in nasal formulation is less critical. The dry powder bi-dose system consists of two profiled blisters that ensure optimum protection against vapor transmission, oxygen and light. The aerodynamic feature combined with easy actuation mode facilitates accurate and constant dosing in terms of expelled amount and inhalation forces.
<Desc/Clms Page number 2>
Delivers evenly over wider surface of nasal mucosa CLAIMS; 1. The inventor claims the delivery of neurologic agents for treatments of disorders such as Alzheimer's disease, Parkinson's disease, Aids, Schizophrenia, affective disorders such as depression, mania, anxietuy, addiction of substances such as opium etc, brain changes associated with age, pain due to head injuries, nerve damage from cardiovascular disorders such as stroke 2. The inventor claims of delivery of vaccines (in particular influenza, vaccines for infectious diseases and diabetes) and peptides (in particular insulin and calcitonin) and new class of biotechnological products.
3. The neurologic agent administered in powder form with the active sprayed or impregnated on carrier. The carrier examined included dextrin, locust bean powder, Soya powder or milk powder.
4. The inventor claims delivery of analgesics including Morphine and new class of
peptides/biotechnology products in spray powder form.
5. The inventor claims pharmaceutical composition of Seratonin (in spray powder form) for nasal delivery for treatment of depression.
6. The inventor claims pharmaceutical composition of Phosphotidyl serine for nasal delivery for enhancement of memory in pharmaceutical composition in spray powder form.
7. The inventor claims the active medicament spray method on carrier's dextrin, lipophilic compounds, chitosan, locust bean powder, Fenugreek powder, Soya flour, spray dried milk etc.
8. The pharmaceutical compositions/or vaccines in powder form sprayed on dextrin, locust bean powder, milk powder or Soya powder etc. for Nasal delivery 9. The inventor claims Nasal Delivery Device comprised of Shaped Nasal Canal (SNC) with inner tube fitting into the capsule containing powder (as shown in Fig 1) in single dose. A new capsule pre-filled with powder dosage can be used for each dose.
The dry powder bi-dose system made of two profiled blisters ensure optimum protection against vapor transmission, oxygen and light. The aerodynamic feature combined with easy actuation mode facilitates accurate and constant dosing in terms of expelled amount and inhalation forces. The system delivers evenly over wider surface of nasal mucosa.
**WARNING** end of DESC field may overlap start of CLMS **.
Claims (1)
- The invention offers innovate delivery of pharmaceutical compositions by Nasal route.**WARNING** end of CLMS field may overlap start of DESC **.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0113725A GB2378383A (en) | 2001-06-06 | 2001-06-06 | Nasal delivery of pharmaceutical compositions in powder form |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0113725A GB2378383A (en) | 2001-06-06 | 2001-06-06 | Nasal delivery of pharmaceutical compositions in powder form |
Publications (2)
Publication Number | Publication Date |
---|---|
GB0113725D0 GB0113725D0 (en) | 2001-07-25 |
GB2378383A true GB2378383A (en) | 2003-02-12 |
Family
ID=9915997
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB0113725A Withdrawn GB2378383A (en) | 2001-06-06 | 2001-06-06 | Nasal delivery of pharmaceutical compositions in powder form |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB2378383A (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2397016A (en) * | 2002-03-19 | 2004-07-14 | Ionix Pharmaceuticals Ltd | Intranasal analgesic composition comprising buprenorphine, & preferably chitosan or partially esterified pectin |
GB2404431A (en) * | 2003-06-24 | 2005-02-02 | John Humphries Parkes | Blast and fragmentation suppression device |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
US8329196B2 (en) | 2002-11-26 | 2012-12-11 | Alk-Abello A/S | Allergen dosage form |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0571671A1 (en) * | 1992-05-26 | 1993-12-01 | The Procter & Gamble Company | A Pharmaceutical composition in powder form |
JPH07101817A (en) * | 1993-08-10 | 1995-04-18 | Mitsui Toatsu Chem Inc | Curable composition for dental use |
WO1995028158A1 (en) * | 1994-04-13 | 1995-10-26 | Janssen Pharmaceutica N.V. | Intranasal antimigraine composition |
WO1996003142A1 (en) * | 1994-07-26 | 1996-02-08 | Danbiosyst Uk Limited | Drug delivery composition for the nasal administration of antiviral agents |
WO1996005810A1 (en) * | 1994-08-20 | 1996-02-29 | Danbiosyst Uk Limited | Drug delivery composition containing chitosan or derivative thereof having a defined z. potential |
EP0943326A1 (en) * | 1996-02-27 | 1999-09-22 | Teijin Limited | Powdery composition for nasal administration |
-
2001
- 2001-06-06 GB GB0113725A patent/GB2378383A/en not_active Withdrawn
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0571671A1 (en) * | 1992-05-26 | 1993-12-01 | The Procter & Gamble Company | A Pharmaceutical composition in powder form |
JPH07101817A (en) * | 1993-08-10 | 1995-04-18 | Mitsui Toatsu Chem Inc | Curable composition for dental use |
WO1995028158A1 (en) * | 1994-04-13 | 1995-10-26 | Janssen Pharmaceutica N.V. | Intranasal antimigraine composition |
WO1996003142A1 (en) * | 1994-07-26 | 1996-02-08 | Danbiosyst Uk Limited | Drug delivery composition for the nasal administration of antiviral agents |
WO1996005810A1 (en) * | 1994-08-20 | 1996-02-29 | Danbiosyst Uk Limited | Drug delivery composition containing chitosan or derivative thereof having a defined z. potential |
EP0943326A1 (en) * | 1996-02-27 | 1999-09-22 | Teijin Limited | Powdery composition for nasal administration |
Non-Patent Citations (1)
Title |
---|
WPI Abstract Accession No 1995-203751/27 & JP7101817A (DOT KK) * |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7666876B2 (en) | 2002-03-19 | 2010-02-23 | Vernalis (R&D) Limited | Buprenorphine formulations for intranasal delivery |
GB2397016B (en) * | 2002-03-19 | 2004-10-27 | Ionix Pharmaceuticals Ltd | Intranasal analgesic composition containing buprenorphine |
GB2397016A (en) * | 2002-03-19 | 2004-07-14 | Ionix Pharmaceuticals Ltd | Intranasal analgesic composition comprising buprenorphine, & preferably chitosan or partially esterified pectin |
US9408805B2 (en) | 2002-11-26 | 2016-08-09 | Alk-Abello A/S | Allergen dosage form |
US8329196B2 (en) | 2002-11-26 | 2012-12-11 | Alk-Abello A/S | Allergen dosage form |
US9415015B2 (en) | 2002-11-26 | 2016-08-16 | Alk-Abello A/S | Allergen dosage form |
US10080719B2 (en) | 2002-11-26 | 2018-09-25 | Alk-Abelló A/S | Allergen dosage form |
US10471008B2 (en) | 2002-11-26 | 2019-11-12 | Alk-Abelló A/S | Allergen dosage form |
US8889176B2 (en) | 2003-01-10 | 2014-11-18 | Depomed, Inc. | Method of managing or treating pain |
US9078814B2 (en) | 2003-01-10 | 2015-07-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US9814705B2 (en) | 2003-01-10 | 2017-11-14 | Depomed, Inc. | Intranasal spray device containing pharmaceutical composition |
US8012505B2 (en) | 2003-02-28 | 2011-09-06 | Alk-Abello A/S | Dosage form having a saccharide matrix |
GB2404431B (en) * | 2003-06-24 | 2008-03-12 | John Humphries Parkes | Blast and fragmentation suppression device |
GB2404431A (en) * | 2003-06-24 | 2005-02-02 | John Humphries Parkes | Blast and fragmentation suppression device |
Also Published As
Publication number | Publication date |
---|---|
GB0113725D0 (en) | 2001-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Kumar et al. | Intranasal drug delivery: A non-invasive approach for the better delivery of neurotherapeutics | |
ES2243094T3 (en) | ADMINISTRATION OF A MODULATED AEROSOLIZED ACTIVE AGENT WITH FLOW RESISTANCE. | |
KR101488025B1 (en) | Sprayable gel-type skin/mucosa-adhesive preparation and administration system using the preparation | |
Alagusundaram et al. | Nasal drug delivery system-an overview | |
US6503481B1 (en) | Compositions for aerosolization and inhalation | |
Wermeling | Intranasal delivery of antiepileptic medications for treatment of seizures | |
SK1502000A3 (en) | Aqueous aerosol preparations containing biologically active macromolecules and method for producing the corresponding aerosols | |
BR0108730A (en) | System, device and method for administering a drug, mouthpiece of a drug delivery device, device for administering multiple unit doses of a drug, methods for preparing a drug delivery system and a drug formulation and for treatment of a patient who needs multiple doses of a drug, drug formulation and multiparticulates | |
ATE307676T1 (en) | A PACKAGING UNIT FOR DRUG ADMINISTRATION IN THE OLFACTORY REGION | |
US11826465B2 (en) | Nebulization formulations for delivery to lower respiratory tract | |
Gandhimathi et al. | Breathable medicine: pulmonary mode of drug delivery | |
EP3590502A1 (en) | Ambroxol dry powder for inhalation use with bronchial target | |
GB2378383A (en) | Nasal delivery of pharmaceutical compositions in powder form | |
JP2023543352A (en) | Nebulizers and atomized antivirals | |
Deshpande et al. | Nasal drug delivery–a review | |
Ruby et al. | Antiemetic drugs as a nasal drug delivery-a review | |
CN100515392C (en) | Dry powder composition for improvement of effective position medical deposit | |
CN101401793B (en) | Capsule type inhalation dust cloud agent | |
Dhakar | Nasal drug delivery: success through integrated device development | |
Yenet et al. | Newer advancement in nasal drug delivery system | |
Varsha et al. | An overview study on nasal and intranasal delivery system of drug | |
Deshmukh et al. | Formulation and Device Design to Increase Nose to Brain Drug Delivery System | |
Shrewsbury | Trends and Advancements in Drug Delivery: What is the" perfect" method of drug delivery? | |
Martini et al. | Nasal and pulmonary drug delivery systems | |
Mittal et al. | Review on nasal drug delivery system |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |